Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs NICE Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.08 (market cap $29.60B), while NICE Ltd trades at $98.25 (market cap $6.02B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.9× NICE Ltd's market cap, and NICE Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NICE | |
|---|---|---|
Market Cap | $29.60B | $6.02B |
Sector | Health | Technology |
52-Week High | $491.22 | $153.44 |
52-Week Low | $205.48 | $83.15 |
Enterprise Value | $27.56B | $5.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
NICE stock trades at $98.36, down 4.1% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $115. The company reported Q2 2026 earnings that beat expectations, with revenue growth of 7.6% year-over-year, and maintains strong profitability with a net income margin of 13.86%. Recent news highlights partnerships with Currys and RingCentral to enhance AI-powered customer engagement.
The outlook for NICE is positive, supported by consistent earnings beats, solid valuation metrics, and expanding AI integrations. Key risks include competitive pressures in the CX software space and potential volatility from macroeconomic factors. With no sell ratings from analysts and institutional interest, the stock presents a growth opportunity amid manageable risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
